MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

The latest financial statement is for the year ending 2025-12-31.

Cash Flow Overview

Free Cash flow
-$10,271,148
Unit: Dollar
Positive Cash Flow Breakdown
    • Net proceeds from issuance of co...
    • Deferred grant funding
    • Depreciation and amortization
    • Others
Negative Cash Flow Breakdown
    • Accrued expenses
    • Principal payments on finance le...
    • Deferred revenue
    • Others

Cash Flow
2025-12-31
Loss from operations
-13,552,334
Sale of royalty and milestone rights, net
0
Interest expense
822,709
Interest income
679,740
Other income (expense), net
296,029
Net loss
-13,399,274
Depreciation and amortization
1,634,486
Right-of-use asset - operating lease
-516,895
Stock-based compensation expense
1,496,562
Loss on disposal of property and equipment
0
Non-cash royalty revenue related to sale of future royalties
-6,298
Non-cash interest expense
82,502
Accounts receivable
12,053
Other receivables
331,026
Prepaid expenses
-668,486
Deposits
0
Other current assets
65,405
Other non-current assets
78,723
Operating lease liability
-548,638
Accounts payable
-255,146
Accrued expenses
-2,250,627
Interest payable
572,561
Deferred grant funding
-3,089,828
Deferred revenue
-1,000,000
Net cash (used in) provided by operating activities
-9,885,870
Purchases of property and equipment
385,278
Net cash used in investing activities
-385,278
Net proceeds from issuance of common stock
20,930,126
Payments of deferred offering costs
321,686
Repayment of liability on sale of future royalties
0
Issuance of note payable
486,721
Payments on note payable
553,829
Principal payments on finance lease
1,264,188
Net cash provided by financing activities
19,277,144
Effect of exchange rate changes on cash and cash equivalents and restricted cash
7,186
Net change in cash, cash equivalents and restricted cash
9,013,182
Cash, cash equivalents and restricted cash, beginning of year
15,998,174
Cash, cash equivalents and restricted cash, end of year
25,011,356
Unit: Dollar.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Net proceeds fromissuance of common stock$20,930,126 Issuance of note payable$486,721 Net cash provided byfinancing activities$19,277,144 Effect of exchange ratechanges on cash and cash...$7,186 Canceled cashflow$2,139,703 Net change in cash,cash equivalents and...$9,013,182 Canceled cashflow$10,271,148 Principal payments onfinance lease$1,264,188 Payments on note payable$553,829 Payments of deferredoffering costs$321,686 Deferred grant funding-$3,089,828 Depreciation andamortization$1,634,486 Stock-based compensationexpense$1,496,562 Prepaid expenses-$668,486 Interest payable$572,561 Right-of-use asset -operating lease-$516,895 Non-cash interestexpense$82,502 Net cash (used in)provided by operating...-$9,885,870 Net cash used ininvesting activities-$385,278 Canceled cashflow$8,061,320 Interest income$679,740 Other income(expense), net$296,029 Net loss-$13,399,274 Purchases of property andequipment$385,278 Canceled cashflow$975,769 Accrued expenses-$2,250,627 Deferred revenue-$1,000,000 Operating lease liability-$548,638 Other receivables$331,026 Accounts payable-$255,146 Other non-currentassets$78,723 Other current assets$65,405 Accounts receivable$12,053 Non-cash royalty revenuerelated to sale of future...-$6,298 Loss from operations-$13,552,334 Interest expense$822,709

Dare Bioscience, Inc. (DARE)

Dare Bioscience, Inc. (DARE)